Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HeraMED Ltd. ( (AU:HMD) ) has shared an update.
HeraMED shareholders have backed the company’s strategic and governance settings at the 2026 annual general meeting, passing all resolutions put to the vote. The outcome underscores continued investor support for the medtech’s focus on digital transformation in women’s and maternity care and its data-driven remote monitoring platform.
Investors approved the remuneration report, elected Dr Sharon Richardson to the board and re-elected chairman Tim Chapman, while also confirming a new auditor and authorising a 10% placement capacity that preserves capital-raising flexibility. Shareholders further endorsed the grant of performance rights and options to key directors and executives, strengthening incentives for leadership to execute HeraMED’s growth and commercialisation plans.
More about HeraMED Ltd.
HeraMED Limited is an Australian-listed medical data and technology company focused on digitally transforming women’s and maternity care. Its proprietary platform combines hardware and software, including the clinically validated in-home fetal and maternal heart rate monitor HeraBEAT, personalised care plans, artificial intelligence and big data to enhance prenatal and postpartum care and reshape the doctor–patient relationship.
The company’s flagship solution, HeraCARE, delivers an integrated women’s health ecosystem aimed at providing better care at lower cost while keeping expectant mothers engaged, informed and supported. It is designed to help healthcare professionals offer high-quality remote monitoring, improve early detection and prevention of risks, and streamline management of maternity pathways across health systems.
YTD Price Performance: 8.33%
Average Trading Volume: 1,773,723
Technical Sentiment Signal: Buy
Current Market Cap: A$45.14M
See more data about HMD stock on TipRanks’ Stock Analysis page.